VOL 38 Supplement No. 1 Archives

FOREWORD

Advancing the Treatment of Anxiety Disorders: New Findings and Novel Uses for Atypical Antipsychotics

Charles B. Nemeroff, MD, PhD

Anxiety disorders are among the most prevalent and disabling psychiatric diagnoses in our society, yet in many ways they remain among the least well-understood of the major mental illnesses. The anxiety disorders are an open...

Pages 6-7 Read Article

Studying Non-Human Primates: A Gateway to Understanding Anxiety Disorders

Ned H. Kalin, MD

Non-human primates, such as the rhesus monkey, provide excellent models of human fear and anxiety because of similarities in behavioral responses and brain function. Studies of rhesus monkeys demonstrate that animals with an anxious temperament...

Pages 8-13 Read Article

Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders

Charles B. Nemeroff, MD, PhD

A large and growing literature suggests that traumatic experiences early in life increase the risk of mood and anxiety disorders in genetically predisposed persons. Findings from laboratory animal studies as well as studies of women...

Pages 14-20 Read Article

Understanding Psychiatric Disorders Through Functional Brain Imaging

Clinton D. Kilts, PhD

Functional brain imaging technologies, such as positron emission tomography (PET) and single-photon emission tomography (SPECT), are widely used to measure hemodynamic and metabolic neural events associated with psychiatric illness or an experimental challenge. Psychopharmacologic treatment...

Pages 21-24 Read Article

Late-Life Anxiety Disorders

Carl Salzman, MD

The prevalence, natural course, risk profile, and treatment of anxiety disorders in the elderly are remarkably understudied. Anxiety disorders are less prevalent in the elderly than in younger adults, but rates of subsyndromal anxiety disorders...

Pages 25-30 Read Article

Unmet Needs in the Treatment of Anxiety Disorders

Mark H. Pollack, MD

There are a number of unmet needs in the treatment of anxiety disorders including the need for more effective, rapidly acting, and better tolerated medications; early identification of nonresponse; effective treatments for refractory disorders; prevention...

Pages 31-37 Read Article

Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics

William H. Carson, MD, Hisashi Kitagawa, PhD, and Charles B. Nemeroff, MD, PhD

Anxiety disorders are prevalent and frequently comorbid with depression. Rates of response and remission for anxiety disorders are low despite marked improvements in treatment in the past several decades. Antidepressants and anxiolytics remain the most...

Pages 38-45 Read Article

Panel Discussion

Pages 46-49 Read Article

VOL 38 Supplement No. 1

Articles in This Issue